Results 41 to 50 of about 292,142 (337)

Effect of fruit smoothie supplementation on psychological distress among people with substance use disorders receiving opioid agonist therapy: protocol for a randomised controlled trial (FruktBAR)

BMC Nutrition, 2022
Background People with substance use disorders generally have unhealthy diets, including limited intake of fruit and vegetables. Evidence shows substantial health benefits from increasing fruit and vegetable consumption on various indicators and possibly
Lars T. Fadnes, Einar Furulund, Karl Trygve Druckrey-Fiskaaen, Tesfaye Madebo, Jørn Henrik Vold, Maria Olsvold, Marianne Cook Pierron, Siv-Elin Leirvåg Carlsen, Rune Blomhoff, Torgeir Gilje Lid, for the ATLAS4LAR Study Group   +10 more
doaj   +1 more source

The challenge of perioperative pain management in opioid-tolerant patients [PDF]

, 2017
The increasing number of opioid users among chronic pain patients, and opioid abusers among the general population, makes perioperative pain management challenging for health care professionals.
Bifulco, F, Coluzzi, Flaminia, Corcione, A., Cuomo, A, Dauri, M, Leonardi, C, Melotti, Rm, Natoli, S, Romualdi, P, Savoia, G   +9 more
core   +2 more sources

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans

CMAJ Open, 2021
Background: Injectable opioid agonist treatment (iOAT) is an emerging evidence-based option in the continuum of care for opioid use disorder in parts of Canada.
Erin Eydt, S. Glegg, Christy Sutherland, K. Meador, M. Trew, Michel Perreault, Marie-Éve Goyer, Bernard Le Foll, Jeffrey Turnbull, N. Fairbairn   +9 more
semanticscholar   +1 more source

Evaluating the effectiveness of concurrent opioid agonist treatment and physician-based mental health services for patients with mental disorders in Ontario, Canada.

PLoS ONE, 2020
ObjectiveThe objective of this study was to evaluate the relationship between concurrent physician-based mental health services, all-cause mortality, and acute health service use for individuals enrolled in Opioid Agonist Treatment in Ontario, Canada ...
Kristen A Morin, Joseph K Eibl, Joseph M Caswell, Brian Rush, Christopher Mushquash, Nancy E Lightfoot, David C Marsh   +6 more
doaj   +1 more source

Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial

Frontiers in Psychiatry, 2022
The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current ...
Christopher S. Stauffer, Christopher S. Stauffer, Christopher S. Stauffer, Salem Samson, Alex Hickok, Alex Hickok, William F. Hoffman, William F. Hoffman, Steven L. Batki   +8 more
doaj   +1 more source

Stigma as a fundamental hindrance to the United States opioid overdose crisis response. [PDF]

, 2019
Alexander Tsai and co-authors discuss the role of stigma in responses to the US opioid ...
Barnett, Michael L, Beletsky, Leo, Keyes, Katherine M, Kiang, Mathew V, McGinty, Emma E, Smith, Laramie R, Strathdee, Steffanie A, Tsai, Alexander C, Venkataramani, Atheendar S, Wakeman, Sarah E   +9 more
core   +2 more sources

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.

Lancet psychiatry, 2021
BACKGROUND Opioid agonist treatment (OAT) reduces many of the harms associated with opioid dependence. We use mathematical modelling to comprehensively evaluate the overall health benefits of OAT in people who inject drugs in Perry County (KY, USA), Kyiv
J. Stone, L. Degenhardt, J. Grebely, S. Larney, F. Altice, P. Smyrnov, A. Rahimi‐Movaghar, M. Alavi, A. Young, J. Havens, W. Miller, M. Hickman, P. Vickerman   +12 more
semanticscholar   +1 more source

BUPRENORPHINE IN OPIOID ADDICTION TEREATMENT: STUDIES WITH METHADONE COMPARISON

Psychiatry and Clinical Psychopharmacology, 2021
Methadone maintenance treatment is the most widely used pharmacological treatment approach for opioid addiction in many countries. In spite of many benefits that was gained after the usage of full agonist methadone, especially high numbers of patients ...
E.Cüneyt Evren, Defne Tamar, Bilge Babayağmur, Duran Çakmak   +3 more
doaj  

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline [PDF]

Canadian Medical Association Journal, 2019
KEY POINTS In 2018, at least 4460 Canadians died from an opioid overdose, of which 94% were determined to be unintentional (accidental) overdoses. This represents a 9% increase in overdose deaths from 2017 and a 48% increase from 2016.[1][1] The recent emergence of street fentanyl, carfentanil ...
Nadia, Fairbairn, Josey, Ross, Michael, Trew, Karine, Meador, Jeff, Turnbull, Scott, MacDonald, Eugenia, Oviedo-Joekes, Bernard, Le Foll, Marie-Ève, Goyer, Michel, Perreault, Christy, Sutherland   +10 more
openaire   +2 more sources

Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing

The International journal on drug policy, 2021
Background The COVID-19 pandemic has exacerbated the opioid crisis. Opioid-related deaths have increased and access to treatment services, including opioid agonist treatment (OAT), has been disrupted.
K. Corace, Kelly D. Suschinsky, Jennifer Wyman, P. Leece, Sue E. Cragg, S. Konefal, Priscille Pana, S. Barrass, A. Porath, B. Hutton   +9 more
semanticscholar   +1 more source